Pharma BD Deal Intelligence
Shire to acquire ViroPharma in strategic move to strengthen rare disease portfolio; will augment already strong growth prospects, paying $50/share, a…
Panmure Gordon's Savvas Neophytou: 'This is the big deal the market had been waiting for' — calls the multiple 'eye watering' but 'strategically very sound,'…
Deal valued at ~58x EBITDA versus biotech sector median of 23x — premium reflects Cinryze growth potential to ~$700M by 2018; positions Shire as #2 globally in…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Shire to acquire ViroPharma at $50/share cash (~$4.2B); 27% premium to prior close. Strengthens rare disease franchise; expected to create $2B rare disease revenue base with $150M annual cost synergies by 2015.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Shire plc / ViroPharma Incorporated (this deal) | 2013 | $4.2B | 58 |
| Shire plc / Dyax Corp. | 2016 | $5.9B | 89 |
| Shire plc / New River Pharmaceuticals Inc. | 2007 | $2.6B | 88 |
| Shire plc / Jerini AG | 2008 | $521M | 85 |
| Shire plc / NPS Pharmaceuticals | 2015 | $5.2B | 78 |
| Shire plc / Baxalta Inc. | 2016 | $32.0B | 77 |
| Shire plc / Movetis NV | 2010 | $565M | 37 |
← Browse all deals · How we score deals
More: 2013 deals · Shire plc deals · Rare Disease deals